A detailed history of Charles Schwab Investment Management Inc transactions in Cor Medix Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 156,549 shares of CRMD stock, worth $1.32 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
156,549
Previous 156,549 -0.0%
Holding current value
$1.32 Million
Previous $677,000 86.71%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

BUY
$4.08 - $6.39 $49,498 - $77,523
12,132 Added 8.4%
156,549 $677,000
Q1 2024

May 08, 2024

SELL
$2.94 - $4.24 $20,218 - $29,158
-6,877 Reduced 4.55%
144,417 $612,000
Q4 2023

Feb 06, 2024

BUY
$3.0 - $4.01 $24,120 - $32,240
8,040 Added 5.61%
151,294 $568,000
Q3 2023

Nov 08, 2023

BUY
$3.6 - $4.46 $67,143 - $83,183
18,651 Added 14.97%
143,254 $530,000
Q2 2023

Aug 09, 2023

BUY
$3.94 - $5.8 $401,876 - $591,594
101,999 Added 451.24%
124,603 $493,000
Q1 2023

May 11, 2023

BUY
$3.22 - $4.61 $27,872 - $39,904
8,656 Added 62.06%
22,604 $93,000
Q2 2022

Aug 15, 2022

SELL
$2.73 - $5.61 $231,345 - $475,402
-84,742 Reduced 85.87%
13,948 $57,000
Q1 2022

May 13, 2022

BUY
$3.83 - $6.24 $16,855 - $27,462
4,401 Added 4.67%
98,690 $541,000
Q2 2021

Aug 16, 2021

BUY
$6.05 - $10.09 $70,851 - $118,163
11,711 Added 14.18%
94,289 $647,000
Q1 2021

May 17, 2021

BUY
$6.84 - $17.58 $13,659 - $35,107
1,997 Added 2.48%
82,578 $825,000
Q4 2020

Feb 16, 2021

BUY
$5.0 - $9.15 $54,115 - $99,030
10,823 Added 15.52%
80,581 $599,000
Q3 2020

Nov 13, 2020

BUY
$3.96 - $6.15 $26,951 - $41,856
6,806 Added 10.81%
69,758 $421,000
Q2 2020

Aug 14, 2020

BUY
$3.08 - $6.56 $9,424 - $20,073
3,060 Added 5.11%
62,952 $397,000
Q4 2019

Feb 07, 2020

BUY
$4.96 - $7.75 $24,358 - $38,060
4,911 Added 8.93%
59,892 $437,000
Q2 2019

Aug 09, 2019

BUY
$5.93 - $10.57 $326,037 - $581,149
54,981 New
54,981 $494,000

Others Institutions Holding CRMD

About CorMedix Inc.


  • Ticker CRMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,208,200
  • Market Cap $347M
  • Description
  • CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of cathet...
More about CRMD
Track This Portfolio

Track Charles Schwab Investment Management Inc Portfolio

Follow Charles Schwab Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.